Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial
Christian U. Blank, Lotte Hoeijmakers, Petros Dimitriadis, S C M A Wijnen, Irene L. M. Reijers, Marta López‐Yurda, Alexander M. Menzies, Annegien Broeks, Sten Cornelissen, Alex Torres Acosta, Anja van der Wal, Robyn P.M. Saw, Judith M. Versluis, Winan J. van Houdt, Michel W.J.M. Wouters, Jurriaan Romano, Elisa A. Rozeman, L. Grijpink-Ongering, Ellen Kapiteijn, Astrid van der Veldt, Karijn P.M. Suijkerbuijk, Hanna Eriksson, Geke A.P. Hospers, Jos A. van der Hage, Dirk J. Grünhagen, Arjen J. Witkamp, Judith Lijnsvelt, W. Martin C. Klop, Charlotte L. Zuur, Annemarie Bruining, Abrahim Al-Mamgani, Thomas E. Pennington, Kerwin F. Shannon, Sydney Ch’ng, Andrew J. Colebatch, Maria Gonzalez, Andrew Spillane, John B.A.G. Haanen, Robert V. Rawson, Richard A Scolyer, Bart A. van de Wiel, Alexander C.J. van Akkooi, Georgina V. Long (2025). Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial. , DOI: https://doi.org/10.21203/rs.3.rs-7090131/v1.
